COLUMBUS, Ohio and BOSTON, April 29, 2025 /PRNewswire/ -- Akita Biosciences, Inc., a consumer health company that develops innovative nasal spray formulations for drug, device, and cosmetic ...
Guard Therapeutics (publ) today announced favorable efficacy results from additional analyses of the Phase 2a AKITA study with the investigational drug candidate RMC-035. The previously reported ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results